Giv As a Novel Prognostic Marker in Stage Ii Colon Cancer

P. Gibbs,P. Ghosh,P. Waring,B. Lafleur,A. Muranyi,S. Singh,P. Brunhoeber,J. Tie,B. Tran,J. Desai, R. Martinez,K. Janssen,A. Goel, S. Hu,V. Teichgräber,U. Rohr,R. Ridder,K. Shanmugam

Annals of oncology : official journal of the European Society for Medical Oncology（2014）

引用 0|浏览22

暂无评分

摘要

Aim: There is an evident unmet need to better define recurrence risk for patients with stage II colon cancer (CC), particularly those with mismatch repair proficient (pMMR) tumors, to determine the subgroup of patients that may benefit from adjuvant chemotherapy. GIV/Girdin is a novel metastasis associated protein that triggers tumor cell invasion by enhancing PI3K/AKT signaling downstream of multiple oncogenic receptors. We explored the potential of GIV as a prognostic marker in stage II CC.

查看译文

关键词

colon,novel prognostic marker,prognostic marker,cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要